Cargando…
Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
Tumor vascularization is an essential modulator of early tumor growth, progression, and therapeutic outcome. Although antiangiogenic treatments appear promising, intrinsic and acquired tumor resistance contributes to treatment failure. Clinical inhibition of the molecular chaperone heat shock protei...
Autores principales: | Bohonowych, J. E., Gopal, U., Isaacs, J. S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902748/ https://www.ncbi.nlm.nih.gov/pubmed/20628489 http://dx.doi.org/10.1155/2010/412985 |
Ejemplares similares
-
Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
por: Bohonowych, Jessica ES, et al.
Publicado: (2011) -
A Novel Extracellular Hsp90 Mediated Co-Receptor Function for LRP1 Regulates EphA2 Dependent Glioblastoma Cell Invasion
por: Gopal, Udhayakumar, et al.
Publicado: (2011) -
Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling
por: Daoud, Abdelkader, et al.
Publicado: (2017) -
Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma
por: Meng, Jing, et al.
Publicado: (2017) -
Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS
por: Nethisinghe, Suran, et al.
Publicado: (2021)